Jane Street’s Aimmune Therapeutics AIMT Stock Holding History

Jane Street’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-159,900	Closed	-$5.51M	–	8518
2020 Q3	$5.51M	Buy	159,900 +85,800	+116%	+$1.83M	﹤0.01%	1747
2020 Q2	$1.24M	Buy	74,100 +46,000	+164%	+$781K	﹤0.01%	3765
2020 Q1	$405K	Buy	28,100 +18,400	+190%	+$470K	﹤0.01%	3880
2019 Q4	$325K	Buy	+9,700	New	+$271K	﹤0.01%	4186
2018 Q3	–	Sell	-7,900	Closed	-$212K	–	5975
2018 Q2	$212K	Buy	+7,900	New	+$242K	﹤0.01%	4504

Jane Street's AIMT Position: Q4 2020 in Review

Jane Street sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 90,855 shares — an estimated $3.13M sold.

Jane Street first reported a position in AIMT in Q3 2015 and held it in 7 quarters. The position peaked at $3.13M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Jane Street reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Jane Street sold 90,855 Aimmune Therapeutics shares in Q4 2020, an estimated $3.13M.
Jane Street first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 7 quarters.
Jane Street's Aimmune Therapeutics position peaked at $3.13M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Jane Street's 13F filing for Q4 2020, filed 17 Feb 2021.